BRPI0715541A2 - mediação de citotoxidade de células evidenciando a expressão de superfície de cd63. - Google Patents
mediação de citotoxidade de células evidenciando a expressão de superfície de cd63.Info
- Publication number
- BRPI0715541A2 BRPI0715541A2 BRPI0715541A BRPI0715541A BRPI0715541A2 BR PI0715541 A2 BRPI0715541 A2 BR PI0715541A2 BR PI0715541 A BRPI0715541 A BR PI0715541A BR PI0715541 A BRPI0715541 A BR PI0715541A BR PI0715541 A2 BRPI0715541 A2 BR PI0715541A2
- Authority
- BR
- Brazil
- Prior art keywords
- surface expression
- cells showing
- showing surface
- cytotoxicity mediation
- mediation
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Reproductive Health (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/493,407 US7534429B2 (en) | 2000-11-29 | 2006-07-26 | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
PCT/CA2007/001317 WO2008011710A1 (en) | 2006-07-26 | 2007-07-24 | Cytotoxicity mediation of cells evidencing surface expression of cd63 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0715541A2 true BRPI0715541A2 (pt) | 2019-09-24 |
Family
ID=38981088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0715541A BRPI0715541A2 (pt) | 2006-07-26 | 2007-07-24 | mediação de citotoxidade de células evidenciando a expressão de superfície de cd63. |
Country Status (10)
Country | Link |
---|---|
US (1) | US7534429B2 (pt) |
EP (1) | EP2073851A4 (pt) |
JP (1) | JP2009544629A (pt) |
KR (1) | KR20090057970A (pt) |
CN (1) | CN101553259A (pt) |
AU (1) | AU2007278791A1 (pt) |
BR (1) | BRPI0715541A2 (pt) |
CA (1) | CA2666464A1 (pt) |
MX (1) | MX2009001014A (pt) |
WO (1) | WO2008011710A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048416B2 (en) * | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7009040B2 (en) * | 2003-01-21 | 2006-03-07 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7175846B2 (en) * | 2003-01-21 | 2007-02-13 | Arius Research Inc. | Cancerous disease modifying antibodies |
EP3421488A3 (en) * | 2012-03-14 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
CN114286686A (zh) * | 2019-07-24 | 2022-04-05 | 艾根奥克思公司 | 与cd63激动剂相关的方法和组合物 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4253880A (en) | 1977-09-23 | 1981-03-03 | U.S. Philips Corporation | Device for the conversion of solar energy into electrical energy |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
MA20406A1 (fr) | 1985-04-09 | 1985-12-31 | Majeste Hassan Ii Roi Du Maroc | Dispositif pour la detection, l'etude et la surveillance de maladies, notamment cardiaques, se traduisant par des manifestations electriquement enregistrables |
EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
NZ222509A (en) | 1986-11-19 | 1993-03-26 | Oncogen | Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen |
US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US5171665A (en) | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
US5296348A (en) | 1989-05-16 | 1994-03-22 | The Wistar Institute Of Anatomy And Biology | Methods for screening monoclonal antibodies for therapeutic use |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
DE69229254T2 (de) | 1991-10-30 | 1999-09-23 | Idemitsu Kosan Co | Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
IL105008A0 (en) | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
CA2154266A1 (en) | 1993-02-05 | 1994-08-18 | John F. Codington | Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy |
JPH10505819A (ja) | 1994-06-24 | 1998-06-09 | ヴラディミール ピー. トーチリン | 腫瘍の治療及び予防のための自己抗体の使用方法 |
US6130276A (en) | 1995-06-07 | 2000-10-10 | Owens Corning Fiberglas Technology, Inc. | Method of reducing fumes from a vessel of molten asphalt |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6783961B1 (en) | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
AU4441799A (en) | 1998-06-15 | 2000-01-05 | Research Foundation Of The State University Of New York, The | Monoclonal antibodies that recognize antigens associated with tumor metastasis |
DE19832998A1 (de) | 1998-07-22 | 2000-02-03 | Siemens Ag | Verfahren zur Ermittlung von in einem kontinuierlichen Datenstrom enthaltenen Datenpaketen |
ES2278463T3 (es) | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
US6068823A (en) | 1999-01-15 | 2000-05-30 | The University Of Houston System | Process for the benign direct fixation and conversion of nitrogen oxides |
CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
US6657048B2 (en) | 1999-10-08 | 2003-12-02 | Arius Research, Inc. | Individualized anti-cancer antibodies |
US20040105816A1 (en) | 1999-10-08 | 2004-06-03 | Young David S. F. | Cancerous disease modifying antibodies |
US7256271B2 (en) | 2003-01-21 | 2007-08-14 | Arius Research Inc. | Cancerous disease modifying antibodies |
US6180357B1 (en) | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
US20020102638A1 (en) | 2000-01-31 | 2002-08-01 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
AU2001253140A1 (en) | 2000-04-03 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Tumor markers in ovarian cancer |
CN1326962A (zh) | 2000-06-05 | 2001-12-19 | 上海博德基因开发有限公司 | 一种新的多肽——人cd63抗原14.63和编码这种多肽的多核苷酸 |
CN1326951A (zh) | 2000-06-05 | 2001-12-19 | 上海博德基因开发有限公司 | 一种新的多肽——人cd63抗原15.07和编码这种多肽的多核苷酸 |
WO2002000677A1 (en) | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
CN1351054A (zh) | 2000-10-26 | 2002-05-29 | 上海博德基因开发有限公司 | 一种新的多肽——人cd63抗原11.11和编码这种多肽的多核苷酸 |
US20060210474A1 (en) | 2000-11-29 | 2006-09-21 | Young David S | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7431923B2 (en) | 2005-01-03 | 2008-10-07 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7361343B2 (en) | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7009040B2 (en) | 2003-01-21 | 2006-03-07 | Arius Research, Inc. | Cancerous disease modifying antibodies |
CN1364803A (zh) | 2001-01-10 | 2002-08-21 | 上海博德基因开发有限公司 | 一种新的多肽——人cd63抗原56.87和编码这种多肽的多核苷酸 |
US20030055220A1 (en) | 2001-01-12 | 2003-03-20 | Pierre Legrain | Protein-protein interactions between Shigella flexneri polypeptides and mammalian polypeptides |
US6783969B1 (en) | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
WO2002086069A2 (en) | 2001-04-20 | 2002-10-31 | Incyte Genomics, Inc. | Secreted proteins |
US7490541B2 (en) | 2001-07-09 | 2009-02-17 | Matsushita Electric Industrial, Co., Ltd. | Compressor |
AU2002324700A1 (en) | 2001-08-14 | 2003-03-03 | Bayer Ag | Nucleic acid and amino acid sequences involved in pain |
NZ573740A (en) | 2001-09-18 | 2010-07-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor, particularly kidney tumor - TAT184 |
AU2002367318B2 (en) | 2002-01-02 | 2007-07-12 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2003068268A2 (en) | 2002-02-14 | 2003-08-21 | Bioinvent International Ab | Treatment, diagnosis and imaging of disease |
AU2003222225A1 (en) | 2002-02-20 | 2003-09-09 | Incyte Corporation | Receptors and membrane-associated proteins |
AU2003227148A1 (en) | 2002-04-05 | 2003-10-27 | Arius Research, Inc. | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer |
AU2003230874A1 (en) | 2002-04-16 | 2003-11-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20060263774A1 (en) | 2002-11-01 | 2006-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US7361342B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
-
2006
- 2006-07-26 US US11/493,407 patent/US7534429B2/en not_active Expired - Fee Related
-
2007
- 2007-07-24 CA CA002666464A patent/CA2666464A1/en not_active Abandoned
- 2007-07-24 BR BRPI0715541A patent/BRPI0715541A2/pt not_active IP Right Cessation
- 2007-07-24 WO PCT/CA2007/001317 patent/WO2008011710A1/en active Application Filing
- 2007-07-24 CN CNA2007800306513A patent/CN101553259A/zh active Pending
- 2007-07-24 JP JP2009521073A patent/JP2009544629A/ja active Pending
- 2007-07-24 AU AU2007278791A patent/AU2007278791A1/en not_active Abandoned
- 2007-07-24 MX MX2009001014A patent/MX2009001014A/es not_active Application Discontinuation
- 2007-07-24 EP EP07784984A patent/EP2073851A4/en not_active Withdrawn
- 2007-07-24 KR KR1020097001776A patent/KR20090057970A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2007278791A1 (en) | 2008-01-31 |
CA2666464A1 (en) | 2008-01-31 |
JP2009544629A (ja) | 2009-12-17 |
KR20090057970A (ko) | 2009-06-08 |
WO2008011710A8 (en) | 2009-04-30 |
US7534429B2 (en) | 2009-05-19 |
EP2073851A4 (en) | 2010-04-21 |
MX2009001014A (es) | 2009-06-22 |
EP2073851A1 (en) | 2009-07-01 |
US20060269481A1 (en) | 2006-11-30 |
CN101553259A (zh) | 2009-10-07 |
WO2008011710A1 (en) | 2008-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10841A (es) | Imidazotriazinas imidazopirimidinas inhibidores de cinasa | |
DE502007002165D1 (de) | Flächensauggreifer | |
GB0613180D0 (en) | Direct laser deposition | |
DK1811245T3 (da) | Modulær solfanger | |
GB0816513D0 (en) | Cytotoxicity mediation of cells evidencing surface expression of cd63 | |
DK2027150T3 (da) | Allo-begrænsede peptid-specifikke t-celler | |
BRPI0811759A2 (pt) | Complemento de chamada | |
AU310092S (en) | Male double jigger | |
ZA200705259B (en) | Cytotoxicity mediation of cells evidencing surface expression of CD63 | |
DK1900519T3 (da) | Trykpresse | |
BRPI0816230A2 (pt) | Mediação citotóxica de evidenciando expressão de superfície de cd9 | |
BRPI0715541A2 (pt) | mediação de citotoxidade de células evidenciando a expressão de superfície de cd63. | |
DK1826164T3 (da) | Lagpresse | |
HUE037324T2 (hu) | Sztochasztikusan lézerezett filmhenger | |
FR2907826B1 (fr) | Pylone de telecommunication | |
FR2902632B1 (fr) | Aspirateur | |
FR2896681B1 (fr) | Aspirateur | |
ES1063581U8 (es) | Estructura de cubierta modular. | |
FR2896679B1 (fr) | Aspirateur | |
AU2006903731A0 (en) | Jigger | |
DK2074606T3 (da) | Sammensat stempel | |
ITFO20060010U1 (it) | Croce fotovoltaica | |
UA14408S (uk) | Печиво «napoleon» | |
ES1062928Y (es) | Pinza | |
ES1064122Y (es) | Articulo de felicitacion personalizable |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |